EAVI2020 EAVI2020 on Twitter EAVI2020 on Facebook EAVI2020 on LinkedIn

Universitätsklinikum Erlangen

Founded in 1815, the University Hospital (Universitätsklinikum) Erlangen (UKER) by now has 42 departments, seven institutes, 24 multidisciplinary institutes and five central service units treating more than 60.000 inpatient and more than 450.000 outpatient cases a year. Each medical institution of UKER is specialised for example in an ascertained clinical picture, a specific treatment or a scientific field. A major research focus of the Universitätsklinikum and the Medical Faculty are infectious diseases and immunology.

Our role in EAVI2020 will be the establishment of liposomal vaccine delivery platformrecruiting heterologous T helper cells, the comparative evaluation of liposomal vaccine delivery platform in small animal models and the design and co-ordination of proof-of-concept phase-I study.

Prof. Dr. Klaus Überla

After postdoctorial training at the Dana-Farber Cancer Institute Klaus spent most of his career working on the molecular biology of HIV and HIV vaccine development. Since 2015, he is heading the Institute of Clinical and Molecular Virology, which was founded by Nobel laureate Prof. Harald zur Hausen and is now one of Germany´s largest academic virus research institutes (http://www.virologie.uk-erlangen.de/en/)

klaus.ueberla@fau.de